Trump Backs Medical Cannabis Protection, Opposes DC Adult-Use Sales

President-elect Donald Trump's emerging cannabis policy framework reveals a nuanced approach that maintains federal protections for state medical marijuana programs while blocking recreational sales in Washington DC. The position reflects Trump's previous support for medical cannabis access combined with a more restrictive stance on adult-use markets in federal jurisdictions.

The medical marijuana protection stance provides regulatory certainty for established operators in the 38 states with legal medical programs. Companies with significant medical operations like Curaleaf (CURLF), Trulieve (TCNNF), and Green Thumb Industries (GTBIF) benefit from continued federal non-interference policies that have allowed state-legal medical markets to flourish without DEA enforcement actions.

Trump's opposition to DC recreational sales creates a complex regulatory patchwork that cannabis companies must navigate. While DC residents can legally possess and consume cannabis, the federal prohibition on commercial sales forces consumers to rely on informal "gifting" markets or travel to neighboring Virginia for licensed purchases. This restriction limits market development opportunities for multi-state operators seeking to establish retail footprints in high-value metropolitan markets.

The policy framework suggests Trump will maintain the Cole Memorandum approach that prioritizes federal resources away from state-compliant cannabis operations. This regulatory stability supports valuations for medical-focused operators while creating uncertainty for companies banking on federal legalization or expanded adult-use access. Medical cannabis markets generate lower per-gram revenues than recreational sales, but offer more predictable regulatory environments and patient loyalty.

Trump's position contrasts sharply with broader industry expectations for federal reform under Democratic leadership. The continued state-federal tension on cannabis policy forces operators to maintain complex compliance structures across multiple jurisdictions while limiting access to traditional banking and capital markets. Medical operators with established state licenses and patient bases maintain competitive advantages in this fragmented regulatory landscape, while pure-play recreational companies face continued federal headwinds.